IL-10 is essential to maintain intestinal homeostasis. CD4 T regulatory type 1 (T1) cells produce large amounts of this cytokine and are therefore currently being examined in clinical trials as T cell therapy in patients with inflammatory bowel disease. However, factors and molecular signals sustaining T1 cell regulatory activity still need to be identified to optimize the efficiency and ensure the safety of these trials. We investigated the role of IL-10 signaling in mature T1 cells in vivo. Double IL-10 Foxp3 reporter mice and transgenic mice with impairment in IL-10 receptor signaling were used to test the activity of T1 cells in a murine inflammatory bowel disease model, a model that resembles the trials performed in humans. The molecular signaling was elucidated in vitro. Finally, we used human T1 cells, currently employed for cell therapy, to confirm our results. We found that murine T1 cells expressed functional IL-10Rα. T1 cells with impaired IL-10 receptor signaling lost their regulatory activity in vivo. T1 cells required IL-10 receptor signaling to activate p38 MAPK, thereby sustaining IL-10 production, which ultimately mediated their suppressive activity. Finally, we confirmed these data using human T1 cells. In conclusion, T1 cell regulatory activity is dependent on IL-10 receptor signaling. These data suggest that to optimize T1 cell-based therapy, IL-10 receptor expression has to be taken into consideration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5263184PMC
http://dx.doi.org/10.4049/jimmunol.1601045DOI Listing

Publication Analysis

Top Keywords

il-10 receptor
24
receptor signaling
20
regulatory activity
12
il-10
10
cells
8
cell therapy
8
inflammatory bowel
8
bowel disease
8
cell regulatory
8
human cells
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!